Endocyte Revenue and Competitors
Estimated Revenue & Valuation
- Endocyte's estimated annual revenue is currently $1.9M per year.
- Endocyte received $101.8M in venture funding in April 2014.
- Endocyte's estimated revenue per employee is $106,083
- Endocyte's total funding is $114.3M.
Employee Data
- Endocyte has 18 Employees.
- Endocyte grew their employee count by 0% last year.
Endocyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.1M | 25 | 0% | N/A | N/A |
#2 | $38.6M | 160 | 4% | N/A | N/A |
#3 | $539.3M | 2281 | 6% | N/A | N/A |
#4 | $2M | 19 | -24% | $1.5M | N/A |
#5 | $2.8M | 27 | -7% | N/A | N/A |
#6 | $3M | 31 | 0% | N/A | N/A |
#7 | $260.5M | 950 | -9% | N/A | N/A |
#8 | $3.3M | 34 | 6% | N/A | N/A |
#9 | $27760M | 39185 | 9% | N/A | N/A |
#10 | $2.6M | 6 | -45% | N/A | N/A |
What Is Endocyte?
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.
keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
$114.3M
Total Funding
18
Number of Employees
$1.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Endocyte News
Consulting or Advisory Role: Bayer, Endocyte, Advanced Accelerator Applications, ORIC Pharmaceuticals, Johnson & Johnson, Curium Pharma,...
Novartis wins FDA OK for radiopharmaceutical drug, cashing in on Endocyte deal. Published March 24, 2022. By Kristin Jensen. Novartis...
Major Players in Cancer Tubulin Inhibitors Market are Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...
The major player of the Cancer Tubulin Inhibitors market (Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...
During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of ...
Other Companies in West Lafayette
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 19 | 36% | N/A |
#2 | $7.2M | 20 | 0% | N/A |
#3 | $3.2M | 21 | -22% | N/A |
#4 | $4.7M | 21 | 5% | N/A |
#5 | $4.1M | 24 | -57% | N/A |
Endocyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-11-22 | $3.5M | Undisclosed | Article | |
| 2004-12-07 | $23.0M | C-2 | Burrill and Company | Article |
| 2006-11-14 | $30.0M | D | Article | |
| 2007-03-26 | $15.0M | C3 | Article | |
| 2008-02-06 | $15.0M | Undisclosed | Oxford Finance Corp, GE Healthcare Financial Servic | Article |
| 2009-10-19 | $26.0M | C | Sanderling Ventures, Burrill & Company | Article |
| 2010-09-01 | $15.0M | Undisclosed | MidCap Financial, Silicon Valley Bank | Article |
| 2011-08-04 | $66.8M | Undisclosed | Article | |
| 2014-03-27 | $Undisclosed | Undisclosed | Credit Suisse Securities (USA) LLC | Article |
| 2014-04-04 | $101.8M | Undisclosed | Article |